Elizabeth A. Mittendorf
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Elizabeth A. Mittendorf has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- George E. Peoples
Department of Surgery, General Surgery Service, Brooke Army Medical Center, Fort Sam Houston, Texas
9 shared publications - Guy T. Clifton
The University of Texas MD Anderson Cancer Center, Houston, TX
5 shared publications - John S. Berry
San Antonio Military Medical Center, San Antonio, TX
5 shared publications Sathibalan Ponniah
5 shared publicationsAlfred F. Trappey
4 shared publicationsErika Schneble
3 shared publications
Latest Publications
- 1 October 2017
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 225 (4) , S23-S24
Final Analysis of a Randomized Phase 1b Trial to Assess Sequencing of the E39 and E39' Vaccines to Optimize Long-Term Antitumor Immunity in Folate Binding Protein (FBP) Expressing Tumors
- 1 October 2017
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 225 (4) , S23-S24
Final Analysis of a Randomized Phase 1b Trial to Assess Sequencing of the E39 and E39' Vaccines to Optimize Long-Term Antitumor Immunity in Folate Binding Protein (FBP) Expressing Tumors
- 1 October 2016
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 223 (4) , S20-S21
Phase Ib Trial Comparing Different Doses and Schedules of a Folate-Binding Protein-Derived Peptide Vaccine, E39, and its Attenuated Version, E39’, to Induce Long-Term Folate-Binding Protein-Specific Immunity in Disease-Free Cancer Patients
- 1 October 2016
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 223 (4) , S20-S21
Phase Ib Trial Comparing Different Doses and Schedules of a Folate-Binding Protein-Derived Peptide Vaccine, E39, and its Attenuated Version, E39’, to Induce Long-Term Folate-Binding Protein-Specific Immunity in Disease-Free Cancer Patients
- 1 May 2016
- Vol. 30 (5) , 475-81, 485
Injecting Hope--A Review of Breast Cancer Vaccines.
There is significant interest in investigating immunotherapeutic strategies to be used for the treatment of breast cancer patients. One form of immunotherapy under active investigation is the cancer vaccine. Vaccines are a form of active immune therapy designed to stimulate the immune system to recognize tumor cells as foreign. Vaccines include an antigen that serves as the target for the immune response, and an immunoadjuvant, which is a nonspecific stimulator of the immune response that promotes an environment conducive to immune stimulation. Vaccines are an appealing therapeutic strategy because they are specific and are associated with minimal toxicity. In addition, they stimulate the adaptive immune system, thereby producing a memory response allowing for sustained effect without repeated therapy. Currently, there are no US Food and Drug Administration-approved breast cancer vaccines; however, there are multiple vaccines and treatment strategies employing these vaccines that are being actively investigated in clinical trials.
- 1 May 2016
- Vol. 30 (5) , 475-81, 485
Injecting Hope--A Review of Breast Cancer Vaccines.
There is significant interest in investigating immunotherapeutic strategies to be used for the treatment of breast cancer patients. One form of immunotherapy under active investigation is the cancer vaccine. Vaccines are a form of active immune therapy designed to stimulate the immune system to recognize tumor cells as foreign. Vaccines include an antigen that serves as the target for the immune response, and an immunoadjuvant, which is a nonspecific stimulator of the immune response that promotes an environment conducive to immune stimulation. Vaccines are an appealing therapeutic strategy because they are specific and are associated with minimal toxicity. In addition, they stimulate the adaptive immune system, thereby producing a memory response allowing for sustained effect without repeated therapy. Currently, there are no US Food and Drug Administration-approved breast cancer vaccines; however, there are multiple vaccines and treatment strategies employing these vaccines that are being actively investigated in clinical trials.
- 1 October 2015
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 221 (4) , S18-S19
Correlation between Robust Local Reactions Prompting GM-CSF Dose Reduction to Clinical Response in a Phase II Trial of the GP2+GM-CSF HER2 Peptide Vaccine to Prevent Breast Cancer Recurrence
- 1 October 2015
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 221 (4) , S18-S19
Correlation between Robust Local Reactions Prompting GM-CSF Dose Reduction to Clinical Response in a Phase II Trial of the GP2+GM-CSF HER2 Peptide Vaccine to Prevent Breast Cancer Recurrence
- 1 October 2014
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 219 (4) , e170
Clinical benefit and safety of boosting the HER2 peptide vaccine (AE37+GM-CSF) in the adjuvant setting to prevent breast cancer recurrence
- 1 October 2014
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 219 (4) , e170
Clinical benefit and safety of boosting the HER2 peptide vaccine (AE37+GM-CSF) in the adjuvant setting to prevent breast cancer recurrence
- 1 October 2014
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 219 (4) , e47
Biomarker correlation to clinical response in a phase II trial of the HER2 peptide vaccine (AE37+GM-CSF)
- 1 October 2014
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 219 (4) , e47
Biomarker correlation to clinical response in a phase II trial of the HER2 peptide vaccine (AE37+GM-CSF)
- 30 September 2013
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 217 (3) , S134
Identification of a regulatory T cell subset that correlates with in vivo and in vitro immune responses in breast cancer patients receiving a CD4-eliciting, HER2 peptide vaccine (AE37)
- 30 September 2013
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 217 (3) , S134
Identification of a regulatory T cell subset that correlates with in vivo and in vitro immune responses in breast cancer patients receiving a CD4-eliciting, HER2 peptide vaccine (AE37)
- 29 February 2008
- Published by Elsevier in Journal of Surgical Research
- Vol. 144 (2) , 180-181
14. Impact of Trastuzumab Treatment on HER2/neu Peptide Vaccination-Preliminary Results for a Combination Immunotherapy
- 29 February 2008
- Published by Elsevier in Journal of Surgical Research
- Vol. 144 (2) , 180-181
14. Impact of Trastuzumab Treatment on HER2/neu Peptide Vaccination-Preliminary Results for a Combination Immunotherapy
- 1 October 2007
- Vol. 13 (10) , CR422-9
Satisfaction with breast cancer screening and future screening participation.
To measure satisfaction with an investigational breast cancer risk screening technique [electrical impedance scanning (EIS)] and to investigate the relationship between satisfaction and willingness to return for follow-up examination one year later. 2727 women volunteers (age 18-45 years, military healthcare beneficiaries) underwent an EIS exam [reported as "negative" (average risk) or "positive" (high risk)]; then they filled out a questionnaire assessing satisfaction with the procedure. One year later, women were invited for follow-up screening. Satisfaction score was significantly related to EIS exam result (higher for women with negative exams), importance assigned to breast cancer screening, and family history of breast cancer. However, satisfaction was not related to scheduling a visit the following year for a follow-up examination. The only satisfaction component predicting return was satisfaction with exam reporting for participants with positive exam results. Return was related positively to age and race/ethnicity; older women and Hispanic women were more likely, while African American women were less likely, to return for follow-up. Factors affecting breast cancer screening participation among younger women are diverse and complex. Further study and delineation of such factors is necessary to understand how best to tailor breast cancer education programs in young women.
- 1 October 2007
- Vol. 13 (10) , CR422-9
Satisfaction with breast cancer screening and future screening participation.
To measure satisfaction with an investigational breast cancer risk screening technique [electrical impedance scanning (EIS)] and to investigate the relationship between satisfaction and willingness to return for follow-up examination one year later. 2727 women volunteers (age 18-45 years, military healthcare beneficiaries) underwent an EIS exam [reported as "negative" (average risk) or "positive" (high risk)]; then they filled out a questionnaire assessing satisfaction with the procedure. One year later, women were invited for follow-up screening. Satisfaction score was significantly related to EIS exam result (higher for women with negative exams), importance assigned to breast cancer screening, and family history of breast cancer. However, satisfaction was not related to scheduling a visit the following year for a follow-up examination. The only satisfaction component predicting return was satisfaction with exam reporting for participants with positive exam results. Return was related positively to age and race/ethnicity; older women and Hispanic women were more likely, while African American women were less likely, to return for follow-up. Factors affecting breast cancer screening participation among younger women are diverse and complex. Further study and delineation of such factors is necessary to understand how best to tailor breast cancer education programs in young women.
- 1 July 2005
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 92 (1) , 85-93
Evaluation of the CD107 cytotoxicity assay for the detection of cytolytic CD8+ cells recognizing HER2/neu vaccine peptides
The recently reported FACS-based CD107 assay has been used in human HIV and CMV antigen models as well as in the ex vivo analysis of tumor cytolytic T cells in a melanoma model by a single group. The purpose of our study was to validate this assay and to use it in previously untested viral and tumor antigen models. Specifically, we investigated the use of the novel CD107 cytotoxicity assay in the detection of influenza and HER2/neu tumor-specific cytolytic CD8+ T cells. CD8+ T cells from HLA-A2+ healthy donors were stimulated with autologous dendritic cells pulsed with FluM or the HER2/neu peptides, E75 or GP2. These CD8+ T cells were then tested in cytotoxicity assays at varying effector:target (E:T) ratios against T2 targets. Cytotoxicity was measured by detection of CD107a and b on the surface of CD8+ T cells. An E:T of 1:5 was found to optimize the resulting percentage of CD8+CD107+ T cells. E75- and GP2-stimulated CD8+ T cells were then tested in cytotoxicity assays with MCF-7 (HER2/neu +HLA-A2+) and AU565 (HER2/neu +HLA-A2-) tumor cells. Cytotoxicity was measured by both the CD107 assay and the 51Cr release assay. Results of cytotoxicity were then correlated between these two assays. In representative experiments, the CD107 assay identified average specific increases for E75- and GP2-stimulated cells of 4.26 and 3.57%, respectively. These results correlated favorably with cytotoxicity as measured by the traditional 51Cr assay. These findings confirm preliminary reports of the CD107 assay and suggest its usefulness for monitoring cancer trials.
- 1 July 2005
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 92 (1) , 85-93
Evaluation of the CD107 cytotoxicity assay for the detection of cytolytic CD8+ cells recognizing HER2/neu vaccine peptides
The recently reported FACS-based CD107 assay has been used in human HIV and CMV antigen models as well as in the ex vivo analysis of tumor cytolytic T cells in a melanoma model by a single group. The purpose of our study was to validate this assay and to use it in previously untested viral and tumor antigen models. Specifically, we investigated the use of the novel CD107 cytotoxicity assay in the detection of influenza and HER2/neu tumor-specific cytolytic CD8+ T cells. CD8+ T cells from HLA-A2+ healthy donors were stimulated with autologous dendritic cells pulsed with FluM or the HER2/neu peptides, E75 or GP2. These CD8+ T cells were then tested in cytotoxicity assays at varying effector:target (E:T) ratios against T2 targets. Cytotoxicity was measured by detection of CD107a and b on the surface of CD8+ T cells. An E:T of 1:5 was found to optimize the resulting percentage of CD8+CD107+ T cells. E75- and GP2-stimulated CD8+ T cells were then tested in cytotoxicity assays with MCF-7 (HER2/neu +HLA-A2+) and AU565 (HER2/neu +HLA-A2-) tumor cells. Cytotoxicity was measured by both the CD107 assay and the 51Cr release assay. Results of cytotoxicity were then correlated between these two assays. In representative experiments, the CD107 assay identified average specific increases for E75- and GP2-stimulated cells of 4.26 and 3.57%, respectively. These results correlated favorably with cytotoxicity as measured by the traditional 51Cr assay. These findings confirm preliminary reports of the CD107 assay and suggest its usefulness for monitoring cancer trials.